Revumenib - REVUFORJ Overseas Generic Drug Situation and Purchasing Reference Instructions Analysis

Revumenib (trade name REVUFORJ) is a new type of small molecule targeted drug, mainly used to treat patients with relapsed / refractory acute leukemia carrying KMT2A rearrangements or NPM1 mutations. By inhibiting key molecular signaling pathways, Revimenib can block tumor cell proliferation and induce apoptosis, providing new treatment options for some high-risk patients. However, the drug has not yet been officially launched in China, so regular domestic hospitals and pharmacies cannot provide the original drug, and patients can only obtain it through overseas channels.

In overseas markets, the main specifications of the original drug tablets of Revemenib include 110mg According to public information, the US version of the original drug is priced at more than 200,000 yuan per box. Because they are high-value innovative drugs, their price levels are relatively high, and coupled with costs related to cross-border transportation and imports, the actual cost of purchasing drugs may further increase. Therefore, if considering obtaining drugs through overseas channels, patients and their families need to fully understand the overall cost and be financially prepared.

Currently, there is no legal or approved generic drug of Revimenib in China. Some so-called "generic drugs" or purchasing information have problems such as low reliability, unstable quality and even legal risks. Therefore, if patients consider purchasing, they should try to choose formal channels and reputable suppliers to ensure that the sources of drugs are authentic and legal, and avoid obtaining them through informal channels to reduce the risk of medication.

In terms of use, since Revimenib is a high-risk drug targeting acute leukemia, genetic testing is required to confirm the indications before use, and treatment is conducted under the guidance of a professional hematologist. During treatment, hematological indicators and liver and kidney functions need to be monitored regularly to deal with possible adverse reactions. Patients should comprehensively evaluate efficacy, cost and safety when making decisions, carefully choose drug purchase channels, and do long-term treatment planning and risk management to ensure the controllability and safety of treatment.

Reference materials:https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/215891s000lbl.pdf